Disc Medicine (NASDAQ: IRON) CEO executes 13,264-share sell-to-cover tax trade

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Executive Officer John D. Quisel reported an open‑market sale of 13,264 shares of common stock at $62.86 per share. According to the filing, this was a "sell to cover" transaction to satisfy tax withholding obligations from vesting restricted stock units and was not a discretionary trade. After the sale, Quisel directly owned 226,064 shares of Disc Medicine common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quisel John D

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		13,264	D	$62.86	226,064	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

	By: /s/ Rahul Khara, as Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Disc Medicine (IRON) report for John D. Quisel?

Disc Medicine reported that CEO John D. Quisel sold 13,264 shares of common stock at $62.86 per share. The filing states this was a sell-to-cover transaction for tax withholding related to vesting restricted stock units, not a discretionary open-market trade.

Why did Disc Medicine (IRON) CEO John D. Quisel sell 13,264 shares?

The sale was executed to cover tax withholding obligations from vesting restricted stock units previously reported. The Form 4 footnote clarifies this was a sell-to-cover transaction and does not represent a discretionary decision by Quisel to reduce his investment in Disc Medicine.

How many Disc Medicine (IRON) shares does CEO John D. Quisel own after this Form 4 sale?

After selling 13,264 shares, John D. Quisel directly owned 226,064 shares of Disc Medicine common stock. This post-transaction balance is disclosed in the Form 4 as the total number of shares beneficially owned following the reported sell-to-cover transaction.

Was the Disc Medicine (IRON) CEO’s recent stock sale an open-market sale?

Yes, the transaction is coded as an open-market or private sale at $62.86 per share. However, the footnote explains it was executed solely to satisfy tax withholding on vesting restricted stock units, characterizing it as a nondiscretionary sell-to-cover transaction.

What does a sell-to-cover transaction mean for Disc Medicine (IRON) insiders?

A sell-to-cover transaction means shares are sold to pay taxes triggered by equity vesting, rather than to change investment exposure. For John D. Quisel, the Form 4 notes the sale covered tax withholding from restricted stock unit vesting and was not a discretionary sale decision.